I~
ishmania infects vertebrate hosts to cause a spectrum of disease ranging from self-limited cutaneous ulceration to fatal progressive disease. Healing and progression of routine leishmaniasis are causally linked to the dissimilar expansion of functionally distinct Thl and Th2 CD4 ~ T lymphocyte subsets during infection (1, 2) . Thl cells producing IFN-3, necessary for control of infection are present in healing tissues, whereas progression of disease is mediated by Th2 CD4 + T lymphocytes that produce IL-4 (3) (4) (5) . The reasons for such host-specific differences in CD4 + T cell differentiation are not well understood. Although IFN-3, and IL-4 are each necessary for the respective expansion of Thl and Th2 cells in vivo (4, 6) , a puzzling aspect of BALB/c susceptibility is that it is not reversed by treatment with rlFN-y during infection (7) . Because IL-12 has both T cell growth and IFN-'y stimulatory properties (8, 9) , we hypothesized that this factor might contribute to the evolution of protective T cell immunity during murine leishmaniasis.
Materials and Methods
Mice. Female BALB/c and C57BL/6 mice (6 wk old) were purchased from Charles River Labs. (Wilmington, MA) and kept in the Cleveland Veterans Administration Medical Center animal care facility.
Cytokine and Antibody Reagents. The rat mAb XMG1.2 (anti-routine IFN-'Ir, IgG1) was a gift from Dr. T. Mosmann (University of Alberta, Edmonton, Canada) and was grown and purified as described (4) . Mouse rlL-12 (sp act, 7.8 x 106 U/rag; endotoxin, 0.5-0.9 EU/mg) was a gift from Dr. S. Wolf (Genetics Institute, Cambridge, MA).
Parasite Cultivation and Antigen Preparation. Leishmania major (WHO strain WHOM/IR/-/173) were grown in M199 containing antibiotics, supplemental glutamine, and 30% FCS (Whittaker Bioproducts, Walkersville, MD) as described (10) . Stationary-phase promastigotes were injected into the hind feet of recipient mice at a dose of 2 x 106 organisms/footpad to initiate infection. The course of infection was monitored 5}, measuring the thickness of footpad swelling weekly using a dial gauge caliper.
Quantitative Parasite Cultures. Approximately 0.1-0.3 g of footpad tissue was minced in 10 ml of M199/30 FCS medium supplemented with 20 ram Hepes (pH 7.4), crushed through a no. 200 stainless steel screen, and disrupted using a Tenbroeck homogenizer (Fisher Scientific, Pittsburgh, PA). 50-/~1 aliquots of footpad or lymph node suspension were sequentially diluted fivefold in promastigote growth medium, placed into flat-bottomed 96-well plates, and incubated at 26~ in humidified room air. Individual wells were examined using an inverted microscope at 200x at 2-d intervals for the presence of motile promastigotes. Data represent the geometric mean and standard error of the last positive reciprocal dilution for each experimental group.
RNA Hybridization. RNA was purified from lymph node tissue and lymphocyte subsets as described (1) . After electrophoresis in a 1% agarose/1.9% formaldehyde denaturing gel, the RNA was transferred to nylon membranes and hybridized with 32p-labeled antisense RNA probes specific for p35 and p40 Ib12, Ib4, and IFN-'7 (4, 9). Generation and Measurement of Lymphokines from Lymph Node Culture. Popliteal lymph nodes from mice infected for 4 wk with L. major and spleens from uninfected mice were disrupted into cellular suspension at 5 x 106 ceUs/ml in DMEM containing 10% FCS, 100 U/ml penicillin, 100/~g/ml streptomycin, and 2 raM glutamine. Each specimen was cultured in media alone or in media with added Con A (4/zg/ml), stationary phase promastigotes (105/ml), or freeze-thaw promastigote antigen (equivalent of 2 x 106 promastigotes/ml). Conditioned media were removed after 48 h, centrifuged to remove cellular debris, and stored at 4~ for assay within 1 wk and/or frozen for later assay. ELISA techniques and reagents for the assay of routine IFN-3' and Ib4 are as described (5) .
Magnetic Selection of CD4 + and CD8 + Lymph Node Cells.
Popliteal lymph node cells were suspended in Mg 2+/Ca2+-free HBSS with 1% FCS added, incubated 30 rain with 10/~g/ml of biotinylated anti-CD4 or anti-CD8 mAb, washed, and gently mixed with avidin-coated magnetic beads on a rotary wheal at 4~ (Dynabeads; Robbins Scientific, Mountain View, CA). Bead-bound lymphocytes were isolated using a magnetic separator (Robbins Scientific), washed once, and resuspended in 6 M guanidine HC1 for RNA extraction. The purity of T calls obtained by this method has been consistently 90-95% for CD4 + and 85-90% for CD8 + T cells (4) . BioassayforlL,12. BALB/c and C57BL/6 mice infected for 3 wk received 100/~g of Salmonella enteritidis LPS (Sigma Chemical Co., St. Louis, MO) by intraperitoneal injection. Serially diluted aliquots of serum were incubated for 48 h with naive BALB/c splenocytes suspended at 107 ceUs/ml in DMEM/10% FCS, and the conditioned media were assayed for IFN-3~ by ELISA. Units of IL-12 activity were defined as the reciprocal dilution of serum at which half-maximal stimulation of IFN-3, release occurred; recombinant murine (rMu)II,-12 was used as an internal standard and positive control. Control serum with or without added LPS did not stimulate IFN-% Activity in serum peaked at 4 h after endotoxin injection. The presence of IL-12 was confirmed by incubation of serum samples in 96-weU culture plates previously coated with nonneutralizing anti-Mulb12 mAb 5C3 (Richard Chizzonite, Hoffmann-La Roche, Inc.) and subsequent measurement of lymphoblast proliferation induced by the captured cytokine as described (11) .
Flow Cytometry. Suspensions of lymph node cells were labeled with rat anti-mouse CD4 (GK1.5; American Type Culture Collection, RockviUe, MD) and anti-mouse CD8 (53-6.72; American Type Culture Collection) mAbs and then with FITC-conjugated anti-rat IgG antisera (mouse serum adsorbed; Kirkegaard & Perry Laboratories, Inc., Gaithersburg, MD) as previously described (4), and analyzed using a FACScan | flow cytometer (Becton Dickinson & Co., Mountain View, CA).
Results and Discussion
To demonstrate a functional role for IL-12 in antileishmanial immunity, we treated BALB/c mice with mouse rlL-12 given by intraperitoneal injection for the first 7 d of infection. Therapy was limited to the first week of infection because discrete Thl and Th2 responses first evolve during this time (12) and because other therapeutic interventions that act to alter CD4 + differentiation, such as treatment with anti-IL-4 and anti-CD4 mAbs, are only effective if given with 1 wk of infection (7, 12, 13) . Treatment of BALB/c mice with either 0.2 and 0.5/~g of rMulL-12 markedly reduced footpad swelling after cutaneous inoculation with the parasite at that site (Fig. 1 ). This correlated with 1,000-10,000-fold decreases in numbers of parasites cultured from homogenized footpad and lymph node tissue ( Table 1) . As defined by decreasing footpad size or parasitic burden at 4-5 wk of infection, 16 of 18 rMulL-12-treated mice healed in comparison with 1 of 18 untreated mice in three separate experiments (89% vs. 5.6%; p < 0.05, Fisher exact test). Approximately two-thirds of cured mice observed for 4 mo remained free of obvious disease and were resistant to reinfection with 2 • 106 stationary-phase promastigotes.
Lymphocytes obtained from the draining lymph nodes of treated mice produced 10-50-fold less IL-4 in response to Con A mitogen and L. major antigen compared with untreated (Table 2 ). Indeed, the Con A response was suppressed below that obtained from uninfected BALB/c spleen cells. IFN-3' production by rMuIL-12-treated mice was variably increased, with the mean values similar or greater than that of control-infected mice (Table 2 ). These data are consistent with a profound suppression of Th2 development in the treated mice, with concomitant sparing or promotion of Thl activity.
Because IFN-'u production was inconsistently enhanced at 4 wk of infection in the rMuIL-12-treated mice, we sought to determine if the protective effects of rMuIL-12 were IFN-3' dependent. A single 1.0-mg dose of anti-IFN-3, mAb XMG1. exacerbates leishmaniasis in normally resistant C57BL/6 and C3H mice (12) . Cotreatment with 1.0 mg of XMG1.2 on the day of infection abrogated the protective effect of rMulL-12 in BALB/c mice, although this exacerbation was delayed by Suspensions of lymph node cells from mice infected for 4 wk and spleen cells from uninfected BALB/c mice were cultured for 48 h in the presence of 4 #g/ml of Con A, 10S/ml of viable promastigotes (Exp. 1), or freeze-thawed antigen equivalent to 2 x 106 promastigotes/ml (Exp. 2). Conditioned media were assayed for IL-4 and IFN-T by ELISA. Cells cultured in media alone yielded cytokine levels <20% of that produced in r~ponse to antigen. Designated BALB/c mice were treated with 0.5 #g of rMulL-12 for the first 7 d of infection. Where specified, 1.0 mg of anti-IFN-')' mAb (XMG1.2) was given as a single dose on the day of infection. * n = 4 mice for control and treated mice. t n = 4 for control, 3 for rMulL-12, and 4 for rMulL-12/anti-IFN-'y-treated mice.
I wk relative to control BALB/c mice (Fig. 2) . This confirmed that the final curative effect of IL-12 is dependent on IFN-7. Draining lymph node cells from mice cotreated with anti-IFN-7 showed restored IL-4 production relative to mice treated with rMulL-12 alone (Table 2) . IL-12 is a growth factor for several lymphocyte populations, including NK cells, 7/~ +, and CD4 + and CD8 + c~/B + T lymphocytes (14) . Although the proportions of lymph node cells that were CD4 + , CD8 +, and surface (s)Ig § (B cells) were not significantly altered in rMulL-12-treated mice compared with untreated mice during infection (34.8 + 12.4 vs. 32.5 + 4.9, 12.4 +_ 1.0 vs. 14.9 _+ 2.6, and 47.5 _+ 7.9 vs. 50.6 + 4.1% respectively, for CD4 + , CD8 +, and slg + lymphocytes), IFN-7 generated by the lymph node cells of rMulL-12-treated mice may have been derived from CD8 + T lymphocytes or NK cells and not from CD4 + Thl cells. Therefore, RNA was harvested after 4 wk of infection from draining lymph node populations separately enriched for CD4 + , CD8 +, and slg + lymphocytes or depleted of these subsets (Other) for hybridization with IFN-7 and IL-4-specific RNA probes (Fig. 3) . Only CD4 + T cells expressed these lymphokine messages during infection. IFN-7 expression was increased twofold in rMulL-12-treated mice, whereas IL-4 production was dimim'shed fourfold as measured by densitometry. Combined with parallel changes observed in the production of cytokines by antigenstimulated lymph node cultures (Table 2) , these results confirm a reversal of Th2 and Thl activities after rMulL-12 therapy. The protective effect of rMulL-12 in susceptible BALB/c mice suggests that increased production of IL-12 may mediate the innate resistance of C57BL/6 mice against progressive leishmaniasis. Indeed, challenge of 3-wk infected mice with LPS resulted in the greater appearance of circulating IL-12 in C57BL/6 mice (400 U/ml) compared with BALB/c mice (<10 U/ml), as measured by bioassay and confirmed by capture of 256 U/ml (or 1.4 ng/ml) of the C57BL/6 activity by specific anti-mouse IL-12 mAb combined with bioassay (11). IL-12 was not detected in the absence of a LPS challenge or in the serum of uninfected mice receiving LPS (~ 10 U/ml). These results are consistent with a greater capacity for IL-12 release as a result of leishmaniasis in resistant mice and were prompted by parallel observations in C57BL/6 and BALB/c mice infected with Bacillus-Calmette-Guerin (15) . Because strongly neutralizing antibodies against murine ILl2 are currently unavailable, we could not confirm if endogenous IL-12 plays a role in C57BL/6 resistance. Furthermore, although IL-12 p35 and p40 mRNA expression was increased in C57BL/6 mice during infection, the p40 and p35 transcripts were associated with different cell populations in the draining lymph nodes (data not shown). Because synthesis of functional IL-12 requires that both subunits be expressed in the same cell, these Northern blot data did not provide easily interpretable conclusions about the in vivo synthesis of IL-12 in response to infection. Further studies are necessary to determine the cellular origin and kinetics of IL-12 release during leishmaniasis.
Our data show that rMulL-12 durably alters CD4 + subset differentiation when given in the critical first week of infection. Although cure was undoubtedly assisted by the increased Thl activity in the draining lymph nodes, the relatively greater negative effect on IL-4 production suggests that considerable benefit may have been provided through removal of a known antagonist of IFN-7-activated macrophage leishmanial killing (16, 17) . The dependence of CD4 + subset outcomes, particularly that of Th2 cells, on IFN-3, after rMulL-12 therapy is consistent with studies showing that IFN-3, is required for both cure and unipolar Thl cell responses in infected C57BL/6 mice (12, 18). However, infected BALB/c mice cannot be cured by treatment with rMulFN-~/ alone (7) , and this suggests that IL-12 may provide separate inductive signals necessary for the appearance of curative T cell responses.
The ability of rMulL-12 to cure leishmaniasis in normally susceptible BALB/c mice strongly supports a unique role for this cytokine in the induction of protective immunity against intracellular parasitic infection. This is the first instance where any recombinant cytokine has been curative for infection with ences in the production of IL-12 during leishmaniasis to the heterogeneity of disease outcomes observed in humans and inbred mice (2, 19) , and to define the role of IL-12 in the pathogenesis of inflammatory and allergic disorders similarly mediated by disparate CD4 + T cell responses.
